Time trends in incidence and prevalence of chronic pancreatitis: A 25‐year population‐based nationwide study

Olesen, Søren Schou; Mortensen, Laust Hvas; Zinck, Elisabeth; Becker, Ulrik; Drewes, Asbjørn Mohr; Nøjgaard, Camilla; Novovic, Srdan; Yadav, Dhiraj; Tolstrup, Janne S

doi:10.1177/2050640620966513

Cited by 35 publications

(25 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prevalence of CP in Europe is shown to be between 16 and 154 per 100,000 ( 11 , 39 , 40 ). A recent study showed the prevalence of CP in the United States to be 73 per 100,000 with a peak of 135 per 100,000 for the 46–55-year age group ( 41 ).…”

Section: Discussionmentioning

confidence: 99%

Acute and Chronic Pancreatitis Disease Prevalence, Classification, and Comorbidities: A Cohort Study of the UK BioBank

Spagnolo

Greer²,

Ohlsen³

et al. 2022

Clin Transl Gastroenterol

View full text Add to dashboard Cite

INTRODUCTION: Pancreatitis is a complex syndrome that results from many etiologies. Large well-characterized cohorts are needed to further understand disease risk and prognosis. METHODS: A pancreatitis cohort of more than 4,200 patients and 24,000 controls were identified in the UK BioBank (UKBB) consortium. A descriptive analysis was completed, comparing patients with acute (AP) and chronic pancreatitis (CP). The Toxic-metabolic, Idiopathic, Genetic, Autoimmune, Recurrent, and severe pancreatitis and Obstructive checklist Version 2 classification was applied to patients with AP and CP and compared with the control population. RESULTS: CP prevalence in the UKBB is 163 per 100,000. AP incidence increased from 21.4/100,000 per year from 2001 to 2005 to 48.2/100,000 per year between 2016 and 2020. Gallstones and smoking were confirmed as key risk factors for AP and CP, respectively. Both populations carry multiple risk factors and a high burden of comorbidities, including benign and malignant neoplastic disorders. DISCUSSION: The UKBB serves as a rich cohort to evaluate pancreatitis. Disease burden of AP and CP was high in this population. The association of common risk factors identified in other cohort studies was confirmed in this study. Further analysis is needed to link genomic risks and biomarkers with disease features in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute and Chronic Pancreatitis Disease Prevalence, Classification, and Comorbidities: A Cohort Study of the UK BioBank

Spagnolo

Greer²,

Ohlsen³

et al. 2022

Clin Transl Gastroenterol

View full text Add to dashboard Cite

show abstract

“…A systematic analysis in 195 countries and territories revealed that the age-standardized prevalence and years lived with disability of overall pancreatitis increased between 1990 and 2017 3 . Therein, the evidence on an increasing trend of CP prevalence was also observed in several countries 4 , 5 . Thus, CP has become a critical public health problem.…”

Section: Introductionmentioning

confidence: 62%

Chronic pancreatitis and cancer risk in a matched cohort study using national claims data in South Korea

Han

Tran

2022

Sci Rep

View full text Add to dashboard Cite

This study aimed to examine the association between chronic pancreatitis (CP) and cancer incidence and mortality among the Korean population. Based on a cancer-free cohort of 8,317,616 individuals between 2002 and 2010, a matched cohort study was conducted, including 10,899 patients with CP, matched for sex and age with 32,697 individuals without CP. The case and control groups were followed up until the date of onset of cancer or death or the end of follow-up date (December 31, 2018). Cox proportional hazards regression was performed to assess the risk of cancer incidence and mortality. Compared to the control group, patients with CP had a higher risk of all cancers with a hazard ratio (HR) of 1.2 [95% confidence interval (CI) 1.1–1.3]. CP was associated with an increased risk of esophageal cancer (HR 3.9, 95% CI 1.8–8.5) and pancreatic cancer (HR 3.9, 95% CI 2.7–5.5) and a decreased risk of colorectal cancer (HR 0.7, 95% CI 0.5–0.9). Regarding cancer mortality, patients with CP had a 1.2-fold risk of all cancer mortality (95% CI 1.1–1.4), compared with the control group. Patients with CP had a higher risk of death from esophageal cancer (HR 3.5, 95% CI 1.5–8.0) and pancreatic cancer (HR 3.3, 95% CI 2.3–4.7) but had a lower risk of death due to stomach cancer (HR 0.4, 95% CI 0.2–0.8). Patients with CP had a higher risk for both incidence and mortality of all cancer types, especially pancreatic and esophageal cancers, compared with the sex- and age-matched control group.

show abstract

“…Moreover, CP is also associated with pancreatic cancer with more than an 8-fold increased probability of tumour development [2]. Epidemiological data have shown an increased incidence of CP in recent years [3,4]. Considering the high disease morbidity and mortality, clinicians should be aware of the risk factors responsible for the onset of the disease.…”

Section: Introductionmentioning

confidence: 99%

“…60-day-old male C57BL6/ cmdb mice (a strain developed in CEM) were subjected to a 12-h dark/light cycle at 22 °C, with free access to water and standard rodent chow ad libitum. We decided to use males because the incidence and prevalence of CP in humans is twice as common in men than in women [3,19]; moreover, cigarette addiction is more common in men.…”

Section: Introductionmentioning

confidence: 99%

The development of cigarette smoke induced chronic pancreatitis in mice is associated with increased expression of K-Ras and NF-κB

Daniluk¹,

Daniluk²,

Rogalski³

et al. 2021

Ann Agric Environ Med.

View full text Add to dashboard Cite

Introduction andObjective. Epidemiological studies have demonstrated a strong association between cigarette smoking (CS) and chronic pancreatitis (CP); however, the exact mechanisms of this phenomenon remains unknown. The authors have previously shown that increased Ras expression activates the NF-κB mediated pathway and promotes development of CP. However, it is unclear whether a similar phenomenon occurs in CS-induced CP. Therefore, the aim of the study was to determine whether CS increases the expression of K-Ras, and promotes the development of CP in mice exposed to repeated episodes of acute pancreatitis (AP). Materials and method. C57BL6/cmdb mice were exposed to CS or a sham treatment for 12 weeks. After one week of exposure, half of the animals from both groups were additionally subjected to repeated cerulein treatment (once a week, for 10 consecutive weeks) to mimic recurrent episodes of AP. Extension of pancreatic damage was determined histologically by H&E and Trichrome staining. The expression of K-Ras protein and downstream components (NF-κB, Cox-2, TGF-β) was evaluated by immunohistochemistry. Results. C57BL6/cmdb mice exposed to CS or cerulein alone did not develop any chronic pancreatic damage. However, concomitant treatment with both of these agents caused focal acinar atrophy, with slight intralobular and perivascular areas of fibrosis, and inflammatory cells infiltration resembling mild CP. Moreover, immunohistochemistry examinations revealed increased pancreatic expression of K-Ras and NF-κB only in mice treated both with CS and cerulein. Conclusions. CS promotes development of CP in mice exposed to repeated episodes of AP. This process may be, at least partially, related to increased expression of K-Ras and NF-κB protein.

show abstract

Time trends in incidence and prevalence of chronic pancreatitis: A 25‐year population‐based nationwide study

Cited by 35 publications

References 37 publications

Acute and Chronic Pancreatitis Disease Prevalence, Classification, and Comorbidities: A Cohort Study of the UK BioBank

Acute and Chronic Pancreatitis Disease Prevalence, Classification, and Comorbidities: A Cohort Study of the UK BioBank

Chronic pancreatitis and cancer risk in a matched cohort study using national claims data in South Korea

The development of cigarette smoke induced chronic pancreatitis in mice is associated with increased expression of K-Ras and NF-κB

Contact Info

Product

Resources

About